title: Anti-HER-2 anti-CD3 bi-specific antibodies inhibit growth of HCT-116 colorectal carcinoma cells in vitro and in vivo.
abstract: OBJECTIVE
  This study is conducted to evaluate the effects of anti-HER-2 anti-CD3 bi-specific antibodies(BsAb) on HER-2/neuover-expressing human colorectal carcinoma cells.
  
  
  METHODS
  Growth was assessed by MTT assays after exposure of HCT-116 cells to Herceptin, anti-CD3 and BsAb antibodies. Immunocytochemistry was applied to test the HER-2 level of HCT-116. In a nude mouse model, HER-2 CD3 BsAb was combined with effector cells (peripheral blood lymph cells from normal human being) for observations on in Vivo growth of tumors.
  
  
  RESULTS
  Compared with the control group, using effector cells combined with anti-CD3 McAb, Herceptin or HER2 CD3 BsAb, tumor cell growth in vitro and in vivo was significantly inhibited (P<0.05), most remarkably in the HER2 CD3 BsAb case. The growth of xenografts with HER2 CD3 BsAb combined with effector cells was also significantly inhibited when compared with the anti-CD3 McAb or Herceptin groups (P<0.05).
  
  
  CONCLUSIONS
  HER-2/neu might be a useful target for immunotherapy in colorectal carcinoma, anti-HER2 anti-CD3 BsAb exerting clear anti-tumor effects.
authors.affiliation: Department of General Surgery, the Second Hospital, Jilin University, Changchun, China. hren2012@sina.com
authors.forename: Hui
authors.initials: H
authors.lastname: Ren
authors.forename: Jun
authors.initials: J
authors.lastname: Li
authors.forename: Jing-Jing
authors.initials: JJ
authors.lastname: Liu
authors.forename: Hui-Ling
authors.initials: HL
authors.lastname: Guo
authors.forename: Tao
authors.initials: T
authors.lastname: Jiang
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000276:immunology* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D017252:CD3 Complex / Q000276:immunology*; D049109:Cell Proliferation; D015179:Colorectal Neoplasms / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D003602:Cytotoxicity, Immunologic; D045325:HCT116 Cells; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D008819:Mice, Nude; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D000068878:Trastuzumab; D023041:Xenograft Model Antitumor Assays
chemical_list: D018033:Antibodies, Bispecific; D061067:Antibodies, Monoclonal, Humanized; D017252:CD3 Complex; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human